Back

Med Learning Group

  • Antibodies, Bispecific
  • Multiple Myeloma

Targeted Synergies: Bispecific Antibody Combinations in Early Relapsed Multiple Myeloma – Academic Track

This enduring activity is designed to enhance the knowledge and clinical competence of academic oncology clinicians in the management of relapsed or refractory multiple myeloma. Expert faculty will examine the mechanistic rationale and clinical evidence supporting the use of bispecific antibodies in early relapse, with emphasis on combination strategies to address resistance mechanisms, patient selection, treatment sequencing, and integration of evolving trial data into individualized treatment strategies. Case-based discussions and audience polling will engage learners in applying key concepts to complex clinical scenarios and addressing challenges related to disease biology, prior treatment exposure, and coordination of care between academic and community practice settings.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 credit

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

No specific specialties targeted.

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • includes Case-based learning
  • Credit · Up to 1 credit
  • Commercial Support
  • Available from
    Nov 13, 2026
  • Last day to claim credit
    Nov 14, 2027 1 year left